VIRX Key Statistics, Chart & Performance
The current stock price of VIRX is 0.0778 USD. In the past month the price decreased by -56.02%. In the past year, price decreased by -87.45%.
VIRX Technical Analysis
VIRX Financial Highlights
Over the last trailing twelve months VIRX reported a non-GAAP Earnings per Share(EPS) of -1.1. The EPS increased by 11.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -197.14% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VIRX Forecast & Estimates
6 analysts have analysed VIRX and the average price target is 3.06 USD. This implies a price increase of 3833.16% is expected in the next year compared to the current price of 0.0778.
VIRX Ownership
About VIRX
Company Profile
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. The company is headquartered in Cardiff-By-The-Sea, California and currently employs 26 full-time employees. The company went IPO on 2005-09-27. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The firm is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
Company Info
VIRACTA THERAPEUTICS INC
2533 S Coast Hwy 101, Suite 210
Cardiff-by-the-Sea CALIFORNIA 94080 US
CEO: Parvinder Hyare
Employees: 40
Phone: 18584008470
VIRACTA THERAPEUTICS INC / VIRX FAQ
What does VIRACTA THERAPEUTICS INC do?
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. The company is headquartered in Cardiff-By-The-Sea, California and currently employs 26 full-time employees. The company went IPO on 2005-09-27. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The firm is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
What is the current price of VIRX stock?
The current stock price of VIRX is 0.0778 USD. The price decreased by -48.65% in the last trading session.
What is the dividend status of VIRACTA THERAPEUTICS INC?
VIRX does not pay a dividend.
How is the ChartMill rating for VIRACTA THERAPEUTICS INC?
VIRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the Price/Earnings (PE) ratio of VIRACTA THERAPEUTICS INC (VIRX)?
VIRACTA THERAPEUTICS INC (VIRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.1).
What is VIRACTA THERAPEUTICS INC worth?
VIRACTA THERAPEUTICS INC (VIRX) has a market capitalization of 3.09M USD. This makes VIRX a Nano Cap stock.